Across TCGA pan-cancer cohorts, GEMIN5 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GEMIN5 data layer compared with 23 for mass-spec protein and 7 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GEMIN5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GEMIN5 expression acts as an unfavorable survival marker.
PDAC, CCRCC, and UCEC are the cancer types where GEMIN5 mass-spec protein most reproducibly stratifies survival.